Bio-Rad Laboratories Operating Margin 2010-2022 | BIO.B

Current and historical operating margin for Bio-Rad Laboratories (BIO.B) over the last 10 years. The current operating profit margin for Bio-Rad Laboratories as of March 31, 2022 is 16.06%.
Bio-Rad Laboratories Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2022-03-31 $2.90B $0.53B 18.37%
2021-12-31 $2.92B $0.49B 16.76%
2021-09-30 $2.98B $0.56B 18.72%
2021-06-30 $2.88B $0.51B 17.74%
2021-03-31 $2.70B $0.44B 16.22%
2020-12-31 $2.55B $0.41B 16.14%
2020-09-30 $2.38B $0.30B 12.39%
2020-06-30 $2.29B $0.24B 10.55%
2020-03-31 $2.33B $0.25B 10.56%
2019-12-31 $2.31B $0.23B 9.90%
2019-09-30 $2.31B $-0.06B -2.47%
2019-06-30 $2.29B $-0.08B -3.41%
2019-03-31 $2.29B $-0.09B -3.93%
2018-12-31 $2.29B $-0.10B -4.50%
2018-09-30 $2.29B $0.18B 7.85%
2018-06-30 $2.28B $0.18B 8.02%
2018-03-31 $2.21B $0.14B 6.19%
2017-12-31 $2.16B $0.12B 5.51%
2017-09-30 $2.11B $0.04B 1.99%
2017-06-30 $2.09B $0.03B 1.49%
2017-03-31 $2.10B $0.06B 2.67%
2016-12-31 $2.07B $0.06B 2.71%
2016-09-30 $2.07B $0.14B 6.58%
2016-06-30 $2.03B $0.14B 6.95%
2016-03-31 $2.02B $0.16B 7.83%
2015-12-31 $2.02B $0.17B 8.22%
2015-09-30 $2.05B $0.16B 7.72%
2015-06-30 $2.11B $0.16B 7.50%
2015-03-31 $2.14B $0.16B 7.67%
2014-12-31 $2.18B $0.15B 6.90%
2014-09-30 $2.18B $0.15B 6.93%
2014-06-30 $2.15B $0.15B 6.82%
2014-03-31 $2.14B $0.15B 7.19%
2013-12-31 $2.13B $0.17B 7.92%
2013-09-30 $2.10B $0.19B 8.94%
2013-06-30 $2.10B $0.23B 10.72%
2013-03-31 $2.08B $0.25B 11.76%
2012-12-31 $2.07B $0.26B 12.76%
2012-09-30 $2.05B $0.29B 14.13%
2012-06-30 $2.06B $0.30B 14.40%
2012-03-31 $2.08B $0.29B 14.07%
2011-12-31 $2.07B $0.31B 14.71%
2011-09-30 $2.06B $0.29B 13.95%
2011-06-30 $2.01B $0.29B 14.31%
2011-03-31 $1.96B $0.29B 14.70%
2010-12-31 $1.93B $0.28B 14.73%
2010-09-30 $1.89B $0.26B 13.87%
2010-06-30 $1.88B $0.25B 13.53%
2010-03-31 $1.84B $0.24B 13.17%
2009-12-31 $1.78B $0.23B 12.89%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $15.121B $2.923B
BIO-RAD LABORATORIES, INC. manufactures and supplies to life sciences research, healthcare, analytical chemistry, semiconductor and other markets a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00